TERN实时信号 | 通过Getagraph.com最大化利润

出售 106052 min ago

@ $6.86

发出时间: 14 Feb 2024 @ 22:30

回报率: -28.43%

上一信号: Feb 10 - 04:54

上一信号: 购买

回报率: -0.72 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	495 961
平均成交量	896 139
市值	317.44M
EPS	$0 ( 2024-03-25 )
下一个收益日期	( $-0.360 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.87
ATR14	$0.00900 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Vivo Opportunity, Llc	Sell	136 255	Common Stock
2024-04-02	Vivo Opportunity, Llc	Sell	76 346	Common Stock
2024-04-03	Vivo Opportunity, Llc	Sell	103 870	Common Stock
2024-04-01	Vivo Opportunity, Llc	Sell	39 411	Common Stock
2024-04-02	Vivo Opportunity, Llc	Sell	22 084	Common Stock

INSIDER POWER
68.20
Last 96 transactions
Buy: 25 215 859 \| Sell: 2 318 163

音量相关性

長: 0.60 (weak)

短: -0.48 (neutral)

Signal:(69.062) Neutral

Terns Pharmaceuticals, 相关性

10 最正相关
SVAC	0.926
EMLD	0.908
ARTEU	0.905
CFFE	0.905
PAIC	0.898
LRMR	0.898
GDST	0.897
ARIZ	0.896
CARG	0.892
LQDA	0.891

10 最负相关
BCAB	-0.929
ATAI	-0.923
CUTR	-0.923
SMFL	-0.92
GMAB	-0.919
MYSZ	-0.919
SRAC	-0.916
SPCX	-0.908
VFF	-0.906
NCBS	-0.903

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Terns Pharmaceuticals, 相关性 - 货币/商品

-0.10
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.30
( neutral )

-0.14
( neutral )

-0.41
( neutral )

Terns Pharmaceuticals, 财务报表

Annual	2023
营收:	$0
毛利润:	$-881 000 (0.00 %)
EPS:	$-1.270

FY	2023
营收:	$0
毛利润:	$-881 000 (0.00 %)
EPS:	$-1.270

FY	2022
营收:	$0
毛利润:	$-1.03M (0.00 %)
EPS:	$-1.670

FY	2021
营收:	$1.00M
毛利润:	$0.00 (0.00 %)
EPS:	$-2.21

Financial Reports:

No articles found.

Terns Pharmaceuticals,

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.